Yesterday
AbbVie Announces Leadership Change with New Appointment TipRanks21:34 13-Dec-24
AbbVie to acquire Roche spinout Nimble in immune drug deal BioPharma Dive16:08 13-Dec-24
AbbVie buys Roche spinout Nimble Therapeutics for $200M FierceBiotech16:03 13-Dec-24
AbbVie makes another small I&I acquisition, buying Nimble for $200M ENDPOINTS14:48 13-Dec-24
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline PR Newswire (Press Release)14:19 13-Dec-24
In the last 7 days
Parkinson's Disease Market is Expected to Showcase a Significant Growth at a CAGR of 5.8% During the Study Period… GlobeNewswire (Press Release)18:04 12-Dec-24
Targeting ovarian cancer with a novel antibody therapeutic European Pharmaceutical Review12:11 12-Dec-24
NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of… Business Wire (Press Release)12:04 12-Dec-24
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever The Motley Fool11:03 12-Dec-24
Betting Big On AbbVie: A Prescription For Growth And Dividends Seeking Alpha01:34 12-Dec-24
RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by… PR Newswire (Press Release)23:19 11-Dec-24
AbbVie Acquires Aliada Therapeutics, Gains Neuroscience Pipeline PharmTech.com19:35 11-Dec-24
AbbVie Completes Acquisition Of Aliada RTT News15:39 11-Dec-24
AbbVie Completes Acquisition of Aliada Therapeutics AbbVie (Press Release)14:18 11-Dec-24
Prestige BioPharma scouts sales expert from AbbVie Korea Biomedical Review05:05 11-Dec-24
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal Zacks15:05 10-Dec-24
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint Clinical Trials Arena11:06 10-Dec-24
AbbVie Logs Another Phase III Success With Tavapadon In Parkinson’s Scrip Pharma Intelligence22:35 9-Dec-24
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences Barchart21:31 9-Dec-24
ASH: Catching up with bispecific rival AbbVie, Roche's subcutaneous Lunsumio matches IV version … FiercePharma20:36 9-Dec-24
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable… PR Newswire (Press Release)17:09 9-Dec-24
#ASH24: AbbVie, Genmab tout Epkinly combinations in earlier lines of non-Hodgkin lymphoma ENDPOINTS17:07 9-Dec-24
AbbVie survey singles out emotional impact of CLL diagnosis on Black, Hispanic and Asian… FiercePharma16:51 9-Dec-24
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study Benzinga16:27 9-Dec-24
AbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover ENDPOINTS16:16 9-Dec-24
AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing FierceBiotech14:58 9-Dec-24
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as … PR Newswire (Press Release)13:04 9-Dec-24
Is AbbVie Stock Underperforming the Dow? Barchart12:30 9-Dec-24
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer… PR Newswire (Press Release)20:01 8-Dec-24
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of… AbbVie (Press Release)00:05 8-Dec-24
In the last month
AbbVie’s Skyrizi retains DTC spending crown, as Novo’s Wegovy sees first entry FiercePharma14:58 6-Dec-24
Former AbbVie boss sells Hidden Hills estate for $22M The Real Deal00:04 5-Dec-24
Intrauterine Devices Market Report Forecasts and Company Analysis 2024-2032, Profiles of AbbVie, Bayer, Teva… GlobeNewswire (Press Release)12:47 4-Dec-24
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock Zacks13:35 3-Dec-24
Biosimilars Gastroenterology Roundup: November 2024 Center for Biosimilars12:16 30-Nov-24
Spotlight on AbbVie: Analyzing the Surge in Options Activity Nasdaq20:46 29-Nov-24
AbbVie Digital Transformation Strategy Report 2024 - Accelerators, Incubators and Other… Business Wire (Press Release)18:06 27-Nov-24
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce Benzinga15:32 26-Nov-24
Alector lays off 17% of staff after AbbVie-partnered Alzheimer’s asset fails phase 2 FierceBiotech10:06 26-Nov-24
Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead Seeking Alpha03:31 26-Nov-24
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating Zacks19:40 25-Nov-24
AbbVie Digital Transformation Strategy Report 2024 - Technology Focus, Technology Initiatives, ICT Budget and Contracts GlobeNewswire (Press Release)16:04 25-Nov-24
AbbVie to Present at Citi's 2024 Global Healthcare Conference AbbVie (Press Release)13:03 25-Nov-24
AbbVie: Upgrading To 'Strong Buy' After Pullback Seeking Alpha00:21 23-Nov-24
AbbVie gains on Leerink Partners upgrade to Outperform Yahoo! US21:33 22-Nov-24
Where Will AbbVie Be in 5 Years? The Motley Fool15:04 19-Nov-24
With new patient resource to close conversation gaps in rheumatic disease, AbbVie makes 'Rheum… FiercePharma15:30 18-Nov-24
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe Zacks14:37 18-Nov-24
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for … Business Wire (Press Release)12:08 18-Nov-24
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip The Motley Fool12:05 18-Nov-24
AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Manufacturing Chemist12:03 18-Nov-24
AbbVie’s Elahere wins European approval for certain ovarian cancers Pharmaceutical Technology11:47 18-Nov-24
AbbVie bags EU nod for key drug from ImmunoGen takeover pharmaphorum11:46 18-Nov-24
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the… PR Newswire (Press Release)06:05 18-Nov-24
Can This Dividend King Ever Hit $400 After This Major Fail? 24/7 Wall St.15:53 17-Nov-24
Dividend King AbbVie Just Paid Investors: Here's How Much They Got 24/7 Wall St.14:17 16-Nov-24
Trump picks RFK Jr. for HHS; AbbVie's psych implosion; Merck tries staving off Summit; and more ENDPOINTS11:04 16-Nov-24
AbbVie doles out awards to support career goals of 20 people living with migraines FiercePharma20:02 15-Nov-24
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global… GlobeNewswire (Press Release)14:39 15-Nov-24
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? Zacks14:33 15-Nov-24
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades' Benzinga14:22 15-Nov-24
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock The Motley Fool10:59 15-Nov-24
Profits drop at Botox plant in Westport as revenues down by 4pc The Irish Independent02:44 15-Nov-24
Profits fall by 27% at Abbvie's Botox plant at Westport Irish Examiner16:30 14-Nov-24
2 Dividend Stocks to Buy Hand Over Fist in November The Motley Fool15:20 14-Nov-24
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations AbbVie (Press Release)13:15 14-Nov-24
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects Seeking Alpha10:31 14-Nov-24

      
            
      
    view more headlines
   
      
      
      
13 Dec 21:34
   
AbbVie News

NewsNow aims to be the world's most accurate and comprehensive aggregator of AbbVie news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.
AbbVie

Latest News

AbbVie News

Biotech Top Stories

UK Top Stories

World Top Stories
